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Abstract
Background: This study aims to investigate the expression and prognostic significance of activator protein 2a (AP-2a) in
gastric adenocarcinoma.
Methodology/Principal Findings: AP-2a expression was analyzed using real-time quantitative PCR (RT-qPCR), western
blotting, and immunohistochemical staining methods on tissue samples from a consecutive series of 481 gastric
adenocarcinoma patients who underwent resections between 2003 and 2006. The relationship between AP-2a expression,
clinicopathological factors, and patient survival was investigated. RT- qPCR results showed that the expression of AP-2a
mRNA was reduced in tumor tissue samples, compared with expression in matched adjacent non-tumor tissue samples
(P=0.009); this finding was confirmed by western blotting analysis (P=0.012). Immunohistochemical staining data indicated
that AP-2a expression was significantly decreased in 196 of 481 (40.7%) gastric adenocarcinoma cases; reduced AP-2a
expression was also observed in patients with poorly differentiated tumors (P=0.001) and total gastric carcinomas
(P=0.002), as well as in patients who underwent palliative tumor resection (P=0.004). Additionally, reduced expression of
AP-2a was more commonly observed in tumors that were staged as T4a/b (P=0.018), N3 (P=0.006), and M1 (P=0.008).
Kaplan-Meier survival curves revealed that reduced expression of AP-2a was associated with poor prognosis in gastric
adenocarcinoma patients (P,0.001). Multivariate Cox analysis identified AP-2a expression as an independent prognostic
factor for overall survival (HR=1.512, 95% CI=1.127–2.029, P=0.006).
Conclusions/Significance: Our data suggest that AP-2a plays an important role in tumor progression and that reduced AP-
2a expression independently predicts an unfavorable prognosis in gastric adenocarcinoma patients.
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Introduction
Gastric cancer is the fourth most common malignant tumor
worldwide, with an estimated one million new cases every year [1].
More new cases of gastric cancer are diagnosed in China each year
than in any other country [2]. Although current practice includes
incorporating chemotherapy or radiation into surgical resection
treatment protocols, gastric cancer survival rates remain poor [3].
Gastric cancer is a heterogeneous disease in both histology and
genetics; hence, patient outcome is difficult to predict using classic
histological classifications. Gastric carcinogenesis is considered to
be a multifactorial and multistep process that involves the
activation of oncogenes and the inactivation of tumor suppressor
genes at different stages of gastric cancer progression. Recently,
several new oncogenes and tumor suppressor genes associated with
gastric cancer have been identified, which may be helpful for early
diagnosis and for the development of targeted therapies [4,5]. To
improve patient prognosis, further understanding of the molecular
mechanisms of cancer progression and the development of new
therapeutic tools based on these mechanisms is required
[4,6,7,8,9].
Transcription factors that have been implicated in the
pathogenesis of malignancy could serve as novel therapeutic
targets [10]. The activator protein-2 (AP-2) family of transcription
factors comprises five 52-kDa isoforms (AP-2a, AP-2b, AP-2c, AP-
2d, and AP-2e) that are encoded by independent genes; AP-2a,
AP-2b and AP-2c are the most studied [11,12,13]. The isoforms
share a common structure: a proline/glutamine-rich transactiva-
tion domain in the N-terminal region and a helix-span-helix
domain in the C-terminal region, which mediates dimerization
and site-specific DNA binding. Depending on the cellular context,
the AP-2 transcription factors are individually associated either
with cell differentiation and development or with cancer
progression/regression. For example, loss of AP-2 expression
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phenotype, which indicates that AP-2 may have a tumor-
suppressive role [14]. In addition, loss of AP-2 expression seems
to be associated with malignant transformation and tumor
progression and is independently associated with an elevated risk
of subsequent metastatic behavior of stage I cutaneous malignant
melanoma [10]. Furthermore, reduced nuclear AP-2 expression
was shown to be associated with disease progression and increased
metastatic capability in breast cancer. In addition, reduced nuclear
AP-2 expression independently predicted an elevated risk of
recurrent breast cancer [12]. In addition, reduced, or loss of, AP-
2a expression has been reported in human cancers of breast,
ovary, colon, brain, and prostate [13,15,16,17,18].
However, to the best of our knowledge, no previous reports exist
concerning the expression status of AP-2a in primary gastric
cancer, and the prognostic value of this protein in gastric cancer
has not yet been assessed. Furthermore, it is important to
investigate whether the correlation found in established cell lines
grown in vitro can also be observed in clinical gastric cancer
specimens.
In the present study, the expression of AP-2a in primary gastric
adenocarcinoma was investigated using quantitative real-time
PCR (RT-qPCR), western blotting and immunohistochemistry.
The relationship between AP-2a expression and the clinicopath-
ological factors, as well as the potential prognostic value of AP-2a
expression in gastric cancer patients, were evaluated.
Results
AP-2a mRNA expression analyzed with RT-qPCR
The transcriptional levels of AP-2a were determined with RT-
qPCR assays on 41 pairs of resected specimens (tumor tissue
samples and matched adjacent non-tumor tissue samples) from
gastric cancer patients. The AP-2a mRNA levels were significantly
reduced in 30 (73%) tumor tissue samples, compared with levels in
the adjacent non-tumor tissue samples (P=0.009, Figure 1).
AP-2a expression analyzed by Western blotting
The AP-2a protein levels in the resected gastric cancer samples
were determined with Western blotting. As shown in Figure 2, a
decrease in AP-2a expression was detected in 28 (68%) of the 41
tumor tissue samples, compared with expression in the matched
adjacent non-tumor tissue samples (P=0.012). These findings
were consistent with those of the RT-qPCR.
The association between AP-2a expression, based on
immunohistochemical staining, and clinicopathological
characteristics
To gain further insight into the effect and prognostic value of
AP-2a expression in gastric cancer patients, paraffin-embedded
tissue sections (n=481) with histopathologically confirmed gastric
adenocarcinoma were examined using immunohistochemistry.
The levels of AP-2a immunoreactivity varied between the tumor
tissue samples and the adjacent non-tumor tissue samples. Positive
AP-2a expression was localized to the cytoplasm in 285 (59.3%) of
the resected tumor tissue samples, whereas the remaining 196
cases (40.7%) displayed reduced cytoplasmic AP-2a expression
(Table 1).
Based on our categories defined in the aforementioned methods,
AP-2a expression was significantly reduced in patients with poorly
differentiated carcinoma (G3) (P=0.001) or with total gastric
carcinoma (P=0.002) and in the patients who underwent
palliative tumor resection (P=0.004). Reduced AP-2a expression
was also observed significantly more frequently in tumors with
deeper invasion (T4a and T4b) (P=0.018) and in cases with
distant metastases (M) (P=0.008) and increased numbers of lymph
node metastases (N3) (P=0.006). Furthermore, 114 of 256 (44.5%)
patients with stage III disease and 33 of 57 (57.9%) patients with
stage IV disease had low AP-2a expression (P,0.001). The
representative photomicrographs are shown in Figure 3.
Correlation between AP-2a expression based on
immunohistochemistry and patient survival
The median survival time of the 481 gastric cancer patients was
46 months (range 3–89 months). The overall survival rate in the
high AP-2a expression group were significantly improved com-
pared to the low expression group (65.3 vs. 46.1%, P,0.001,
Figure 4).
Univariate and multivariate analyses
Univariate and multivariate analyses were performed to
compare the impact of AP-2a expression and other clinicopath-
ological parameters on prognosis. Based on univariate analysis that
included all 481 patients, 9 factors were found to have statistically
significant associations with overall survival; these included tumor
location, tumor size, histological grade, radical resection, AP-2a
expression, chemotherapy, and the T, N, and M stage based on
the 7
th edition of the UICC TNM classification (Table 1). All 9
factors were included in a multivariate Cox proportional hazards
Figure 1. RT-qPCR analysis of AP-2a expression in gastric
cancer patients. Relative expression of AP-2a in gastric cancer tumor
tissues compared to adjacent non-tumor tissues (n=41) assessed by RT-
qPCR (P=0.009).
doi:10.1371/journal.pone.0024897.g001
Figure 2. Western blotting analysis of AP-2a expression in
gastric cancer patients. Relative expression of AP-2a in gastric cancer
tumor (T) tissues compared to adjacent non-tumor (N) tissues (n=41)
assessed by western blotting, (P=0.012).
doi:10.1371/journal.pone.0024897.g002
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tumor location, tumor size, AP-2a expression, T, N, and M stage
remained independent prognostic factors (Table 2). The relative
risk of death in patients with AP-2a-negative tumors was 1.512
times higher than that of patients with AP-2a-positive tumors
(HR=1.512, 95% CI=1.127–2.029). Histological grade, radical
resection, and chemotherapy, which were significant prognostic
factors in the univariate analysis, did not show significant influence
based on the multivariate analysis. We think that that the
prognostic value of radical resection was overlapped by the M
stage, and thus it did not show significant influence based on the
multivariate analysis. Although patients in the adjuvant chemo-
therapy treatment group showed better overall survival rates based
on the univariate analysis (P=0.042), the lack of statistical
significance in the multivariate analysis likely reflects a selection
bias because adjuvant chemotherapy was more commonly
administered to patients with advanced-stage disease.
Discussion
Tumor progression depends on factors that are intrinsic to the
tumor cells, including, but not limited to, growth factors and their
cognate receptors, extracellular matrix proteins, proteases, che-
mokines, and cellular adhesion molecules. The expression of these
factors is influenced by the environment and the microenviron-
ment, as well as by genetic and epigenetic factors. The
transcription factor AP-2a has been shown to regulate many of
the genes that are involved in normal cellular hemostasis [11,15].
Therefore, the loss of AP-2a expression may result in dedifferen-
tiation, proliferation, and eventually, metastasis or invasion
[10,12,18]. Previously, AP-2a has been reported to possess tumor
suppressive properties in breast cancer, ovarian cancer, prostate
cancer and some other malignant tumors. However, to date, the
prognostic significance of AP-2a in gastric cancer has not yet been
evaluated.
In the present study, we investigated AP-2a mRNA and protein
expression in primary gastric cancer specimens by RT-qPCR and
western blotting detection, respectively. The transcriptional levels
of AP-2a were determined with qRT-PCR and western blotting
assays on 41 pairs of resected specimens (tumor tissue samples and
matched adjacent non-tumor tissue samples) from gastric cancer
patients. The results showed that the AP-2a mRNA and protein
levels were significantly reduced in 30 (73%) and 28 (68%) tumor
tissue samples, compared with levels in the adjacent non-tumor
tissue samples (P=0.009 and 0.012, respectively). These findings
were consistent between RT-qPCR and western blotting detec-
tions. These observations support a previous hypothesis that AP-2a
might be a tumor suppressor, and also suggest that AP-2a might
play an important role in the tumorigenesis of gastric cancer.
Furthermore, in our study, which encompassed a relatively large
series of gastric cancer patients (n=481), we strengthened the
hypothesis that AP-2a acts as a tumor suppressor in gastric cancer
because low AP-2a expression was associated with poorly
differentiated adenocarcinoma (G3), total gastric cancer, greater
tumor progression (T4a/b and N3) and metastatic behavior (M1).
Patients with low AP-2a expression were more likely to have stage
III (44.5%) and IV (57.9%) disease than do patients with high AP-
2a expression. These results are consistent with the findings of Gee
et al. [19] and Pellikainen et al. [12], who described an association
between high AP-2 expression and high differentiation in breast
cancer, including a low mitotic count and high histological grade
(G1–G2). Similar findings have also been reported for other
malignancies [10,17,18,20]. Therefore, it seems that AP-2a maybe
a potential tumor-suppressor gene involved in gastric cancer.
In the Kaplan–Meier survival analysis, patients with low AP-2a
expression had a significantly shorter overall survival than those
with high expressions. Univariate analyses showed that the
decreased expression of AP-2a in gastric cancer tissues was
significantly associated with overall survival rate. Multivariate
analysis demonstrated that AP-2a expression, together with some
Table 1. Relationship between AP-2a expression and
clinicopathologic features of patients with gastric cancer.
Variables Number
AP-2a
expression P value
Low High
Age(years) 0.192
#60 270 117 153
.60 211 79 132
Gender 0.446
Male 326 129 197
Female 155 67 88
Tumor size (cm) 0.449
#5.0 309 122 187
.5.0 172 74 98
Histological grade 0.001
*
Well differentiated (G1) 18 3 15
Moderately differentiated (G2) 166 45 121
Poorly differentiated (G3) 297 148 149
Location 0.002
*
Proximal 271 106 165
Distant 186 72 114
Total 24 18 6
Radical resection 0.004
*
Yes 410 156 254
No 71 40 31
Tumor invasion (T) 0.018
*
T1 35 12 23
T2 43 13 30
T3 98 33 65
T4a 256 109 147
T4b 49 29 20
Nodal status (N) 0.006
*
N0 135 44 91
N1 94 36 58
N2 107 40 67
N3 145 76 69
Metastasis status (M) 0.008
*
M0 425 164 261
M1 56 32 24
TNM Staging ,0.001
*
Stage I 50 14 36
Stage II 118 35 83
Stage III 256 114 142
Stage IV 57 33 24
*Statistically significant (P,0.05).
doi:10.1371/journal.pone.0024897.t001
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tumor depth, lymph node status, and metastasis status, were
independent risk factors in the prognosis of gastric cancer patients.
These results suggest that decreased AP-2a expression might help
identify gastric cancer patients with a poor prognosis, and could
therefore be a novel prognostic marker of gastric cancer patients.
In our study of gastric adenocarcinoma, we observed exclusively
a cytoplasmic expression pattern of AP-2a proteins. However, both
cytoplasmic and nuclear AP-2a expression have been previously
described in several other malignancies [10,12,17,20,21]. In
ovarian cancer, high cytoplasmic AP-2a expression is associated
with a favorable prognosis; furthermore, in ovarian cancer,
nuclear expression with low cytoplasmic expression is associated
with an increased risk of death [17]. In breast cancer, combined
cytoplasmic and nuclear AP-2a expression may provide important
additional information on the prognosis and behavior of the
disease [12]. In malignant melanomas, AP-2 expression was shown
exclusively nuclear expression [10]. In prostate carcinomas, the
expression of AP-2 was cytoplasmic in the majority of cases and
nuclear expression of AP-2 was present in 22% of the tumors [20].
However, both in colorectal and prostate carcinomas, cytoplasmic
AP-2 had been reported to have no prognostic value [20,21]. As
for the reason of above contradict results, we suppose that
immunohistochemistry may only evaluate the end products of
gene expression. Methodological factors, like antigen specificity,
tissue processing and heterogeneity of different kind of malignancy
may interfere with these results. Also, this phenomenon may
partially due to modifications in the nuclear-pore complexes or in
the activity of the transport receptors (karyopherines/importins/
exportins) or changes of the AP-2a protein itself. In our results,
reduced cytoplasmic expression of AP-2a predicted poor patients’
outcome, suggesting that decrease of AP-2a transcription/
translation or increased turnover rate are a more likely course
than translocation in the case of gastric adenocarcinoma.
Figure 3. Immunohistochemical detection of the AP-2a protein expression in gastric cancer and surrounding non-tumor tissues. (A)
Normal gastric tissues, scored as AP-2a (+++); (B) Well-differentiated gastric cancer, scored as AP-2a (++) according to the criteria defined in material
and methods section; (C) moderately differentiated gastric cancer, scored as AP-2a (+); (D) poorly differentiated gastric cancer, scored as AP-2a (2); (E)
Immunostaining of gastric cancer and adjacent non-tumor tissues showing a sharp contrast between infiltrative tumor areas of negative staining and
the adjacent tissue of positive staining. Original magnification: A–D6200; E6100.
doi:10.1371/journal.pone.0024897.g003
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amounts of functional AP-2a and other cellular factors were not
extensively investigated in the present study, the relatively large
number of uniformly-treated patients strengthens the value of the
current findings and significantly increases our knowledge of
gastric adenocarcinoma patients.
In conclusion, the present study suggests that low AP-2a
expression independently predicts worse overall survival in
patients with gastric adenocarcinoma. However, the molecular
mechanisms involved in the regulation of AP-2a expression in
gastric cancer require further investigation. Future work in this
field is necessary because greater understanding of AP-2a function
in malignant transformation has the potential to improve
prognostication in gastric cancer patients.
Materials and Methods
Ethics statement
The study was approved by the Ethics Committee of Sun Yat-
sen University Cancer Center, and written informed consent was
obtained from each subject.
Patients
From January 2003 to December 2006, clinicopathological data
from 481 gastric cancer patients who underwent surgical resection at
Sun Yat-sen University Cancer Center were retrospectively analyzed.
Patients who met the following eligibility criteria were included: (1)
diagnosis of gastric adenocarcinoma identified by histopathological
examination; (2) surgical history that included gastrectomy plus
lymphadenectomy (limited or extended); (3) availability of complete
follow-up data; (4) no preoperative treatment, such as chemotherapy
and radiotherapy; (5) no history of familial malignancy or other
synchronous malignancy (such as GIST, esophageal cancer, and
colorectal cancer); (6) no recurrent gastric cancer and remnant gastric
cancer; and (7) no death in the perioperative period. Tumor resection
and D2 lymphadenectomy were performed by experienced surgeons,
and the surgical procedures, which followed the Japanese Gastric
Cancer Association (JGCA) guidelines [22], were similar in all
patients who underwent radical resections.
Tissue specimens
Fresh gastric cancer and adjacent non-tumor tissue samples
(n=41) were obtained from 41 gastric cancer patients who
underwent surgical resection at the Sun Yat-sen University Cancer
Center between 2005 and 2006. These 41 patients included 27
males and 14 females, with a median age of 50 years (range, 21–75
years). After surgical resection, the fresh tissue samples were
immediately immersed in RNAlater (Ambion Inc., USA) and stored
at 4uC overnight to allow thorough penetration of the tissues; the
samples were then frozen at 280uC until RNA extraction. Both the
Figure 4. Kaplan–Meier survival curves of gastric cancer
patients (n=481) after surgical resection. Decreased AP-2a
expression correlated with poor patient survival. Patients in high AP-
2a expression group exhibited significantly better survival than the low
AP-2a expression group (log-rank test: P,0.001).
doi:10.1371/journal.pone.0024897.g004
Table 2. Univariate and multivariate survival analysis of clinic-pathologic variables in 481 cases of gastric carcinoma patients.
Variables Univariate analysis Multivariate analysis
HR 95%CI P value HR 95%CI P value
Gender (male vs. female) 1.196 0.894–1.600 0.227
Age (year), ($60 vs. ,60 ) 1.293 0.979–1.707 0.070
Location (distal/proximal/total) 0.725 0.558–0.940 0.015* 0.725 0.561–0.938 0.014*
Size (cm) (.5 vs. #5) 1.888 1.429–2.496 ,0.001* 1.397 1.046–1.867 0.024*
Differentiation (G3/G2/G1) 1.376 1.060–1.786 0.017* 1.166 0.869–1.566 0.306
Radical resection (No vs. Yes) 4.603 3.373–6.282 ,0.001* 1.312 0.659–2.610 0.439
AP-2a (low vs. high) 1.866 1.413–2.466 ,0.001* 1.512 1.127–2.029 0.006*
T (T4b/T4a/T3/T2/T1) 1.784 1.504–2.117 ,0.001* 1.469 1.210–1.784 ,0.001*
N (N3/N2/N1/N0) 1.574 1.387–1.787 ,0.001* 1.318 1.151–1.509 ,0.001*
M (M1 vs. M0) 5.501 3.951–7.659 ,0.001* 3.071 1.482–6.362 0.003*
Chemotherapy (No vs. Yes) 1.319 0.986–1.765 0.042* 0.972 0.714–1.322 0.856
*Statistically significant (P,0.05).
doi:10.1371/journal.pone.0024897.t002
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more than 2 cm away from the gastric cancer, were sampled and
then verified by pathological examination.
Paraffin-embedded samples were obtained from 481 gastric
cancer patients who underwent surgical resection at the Sun Yat-
sen University Cancer Center between 2003 and 2006. These
patients included 326 male and 155 female patients, with a median
age of 58 years (range, 17–85 years). Each tumor sample was
assigned a histological grade based on the World Health
Organization (WHO) classification criteria. All patients were
staged using the 7th edition of the International Union Against
Cancer (UICC) Tumor-Node-Metastasis (TNM) staging system.
Extraction of total RNA and RT-qPCR
Total RNA was extracted using TRIzol solution (Invitrogen,
USA) according to the manufacturer’s protocol. RNAse-free
DNAase I was used to eliminate DNA contamination. Total
RNA concentration and quantity were assessed by absorbency at
260 nm using a NANO DROP spectrophotometer (ND-1000,
Thermo Scientific, USA) and the purity of the samples was
estimated by the OD ratios (A260/A280, ranging within 1.8–2.2),
visualized on an agarose gel to check quality. Reverse transcription
(RT) was performed in a 25 ml reaction volume with 2 mg total
RNA treated with 0.5 mg of Oligo(dt), 200 U M-MLV reverse
transcriptase, 25 U RNase inhibitor and 2.5 mM dNTP to
synthesize first-strand cDNA (Promega, USA), according to the
manufacturer’s recommendations. The reaction system was
incubated at 70uC for 5 minutes (primer annealing), 42uC for
1 hour (synthesis) and resulting cDNA was stored at 220uC. The
resulting cDNA was subjected to RT-qPCR for the evaluation of
the relative expression levels of GAPDH (as an internal control)
and AP-2a. The sequences of the sense and antisense primers were
as follows: 59-AGGGCGAAGTCTAAAAATGGAG- 39 (F) and
59- TAGTGATGTGAGCAGGGTAACG-39(R) for AP-2a;5 9-
CTCCTCCTGTTCGACAGTCAGC-39(F) and 59- CCCAA-
TACGACCAAATCCGTT -39(R) for GAPDH, and the corre-
sponding PCR products were 114 bp and 113 bp, respectively.
Gene-specific amplification was performed using an Applied
Biosystems (ABI 7900HT) RT-qPCR machine that measured
the binding of SYBR Green I to double-stranded DNA. Each
sample was tested with a no template control (NTC) for each pair
of oligonucleotide primers to control contamination or primer-
dimers, and each experiment was repeated at least twice using
cDNA samples from separate reverse transcription reactions.
The reactions were performed in a total volume of 15 ml that
contained the following: 0.5 ml cDNA that was synthesized as
described above, 7.5 mlo f2 6SYBR Green master mix (Invitro-
gen, USA), and 200 nM of each pair of oligonucleotide primers.
The amplification was performed as follows: an initial step at 95uC
for 10 min, followed by 45 cycles of 95uC for 30 sec and 60uC for
60 sec. Regression curves were calculated for each sample, and the
amplicated sample’s relative quantity was calculated from the
threshold cycles using the instrument’s software (SDS 2.0). The
RT-qPCR amplicons were analyzed with gel electrophoresis to
confirm the specificity of the generated products. Relative
expression levels of the target genes were normalized to the
geometric mean of the internal control gene, GAPDH. The
generated data were averaged and expressed in relative units of
normalized expression. Data were analyzed using the comparative
threshold cycle (22DDCT) method.
Western blotting analysis
The frozen tissue samples from patients with gastric cancer
including the tumor and non-tumor tissue, were homogenized in
RIPA lysis buffer, and the lysates were cleared by centrifugation
(12,000 rpm) at 4uC for 15 min. Approximately 40-mg protein
samples were run on a 12% SDS-PAGE gel and were transferred
to PVDF membranes. After blocking non-specific binding sites for
60 min with 5% non-fat milk, the membranes were incubated
overnight at 4uC with a primary polyclonal antibody against AP-
2a at a 1:2000 dilution). The membranes were then washed three
times with TBST for 10 min each and probed with HRP-
conjugated secondary antibody (at a 1:2000 dilution) for 60 min at
room temperature. The membranes were then washed three times
with TBST and developed with an enhanced chemiluminescence
system (ECL, Pierce).
Immunohistochemistry
Formalin-fixed, paraffin-embedded samples were sectioned at a
thickness of 2 mm, and the sections were deparaffinized and
rehydrated using graded ethanols. For antigen retrieval, the slides
were boiled in EDTA (1 mM; pH 8.0) for 15 min in a microwave
oven. Endogenous peroxidase activity was blocked with 0.3%
hydrogen peroxide solution for 10 min at room temperature. After
rinsing with PBS, the slides were incubated overnight at 4uC with
a 1:500 dilution of rabbit anti-AP-2a monoclonal antibody (Santa
Cruz, USA). After three washes in PBS, the sections were
incubated with biotinylated secondary antibody (Zhongshan
Golden Bridge Biotech., Beijing, China) for 30 min at room
temperature. Finally, the visualization signal was developed with
3,39-diaminobenzidine tetrahydrochloride (DAB), and all of the
slides were counterstained with hematoxylin.
Semi-quantitative methods
The specimens were analyzed by three observers (W. W., L. L.,
and Y.Z.) who were blinded to the patients’ clinical outcomes.
Discrepancies between the observers were found in less than 10%
of the examined slides, and consensus was reached after further
review. The total AP-2a immunostaining score was calculated as
the sum of the percent positivity (the percentage of the positively
stained tumor cells) and the staining intensity. The percent
positivity was scored as ‘‘0’’ (,5%, negative), ‘‘1’’ (5–25%,
sporadic), ‘‘2’’ (25–50%, focal), or ‘‘3’’ (.50%, diffuse). The
staining intensity was scored as ‘‘0’’ (no staining), ‘‘1’’ (weakly
stained; visible at high magnification), ‘‘2’’ (moderately stained;
visible at low magnification), or ‘‘3’’ (strongly stained; strikingly
positive at low magnification). The total AP-2a immunostaining
score was calculated with the value of percent positivity
score6staining intensity score, which ranged from 0 to 9. We
defined the high AP-2a expression level as a total score $4, and
low AP-2a expression as a total score ,4.
Follow-Up
Postoperative follow-up occurred at our outpatient department
and included clinical and laboratory examinations every 3 months
for the first 2 years, every 6 months during the third to fifth years,
annually for an additional 5 years or until patient death, whichever
occurred first. Overall survival, which was defined as the time
from the operation to the patient’s death or the last follow-up, was
used as a measure of prognosis.
Statistical analysis
A paired-samples t-test was used to compare the AP-2a mRNA
levels in the tumor tissue samples and the adjacent non-tumor
tissue samples. The x2 test for proportion and Pearson’s
correlation coefficients were used to analyze the relationship
between AP-2a expression and various clinicopathological char-
AP-2a in Gastric Adenocarcinoma
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Kaplan-Meier method and were analyzed with the log-rank test.
Cox proportional-hazard analysis was used for univariate and
multivariate analysis to explore the effect of clinicopathological
variables and AP-2a expression on survival. A two-sided P-
value,0.05 was considered to be statistically significant. All
statistical analyses were performed with SPSS software (version
16.0; SPSS Inc., Chicago, IL, USA).
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